Do analysts rate BTMD or SYRA?

biote currently has a consensus price target of $2.50, indicating a potential upside of 104.92%. Given biote's stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than Syra Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, BTMD or SYRA?

biote has higher revenue and earnings than Syra Health. biote is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.23 $27.05M $0.11 11.09 Syra Health $7.98M 1.52 -$2.94M $0.01 87.77

Is BTMD or SYRA more profitable?

biote has a net margin of 3.19% compared to Syra Health's net margin of -54.90%. biote's return on equity of -22.33% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets biote 3.19% -22.33% 12.10% Syra Health -54.90% -131.94% -99.19%

Do analysts prefer SYRA or PRPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, SYRA or PRPO?

Precipio has higher revenue and earnings than Syra Health. Precipio is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syra Health $7.98M 1.52 -$2.94M $0.01 87.77 Precipio $24.05M 1.76 -$360K -$0.64 N/A

Is SYRA or PRPO more profitable?

Precipio has a net margin of -4.47% compared to Syra Health's net margin of -54.90%. Precipio's return on equity of -8.49% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets Syra Health -54.90% -131.94% -99.19% Precipio -4.47% -8.49% -5.75%

Do analysts prefer RYOJ or SYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, RYOJ or SYRA?

RYOJ has higher revenue and earnings than Syra Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 4.72 $120K N/A N/A Syra Health $7.98M 1.52 -$2.94M $0.01 87.77

Is RYOJ or SYRA more profitable?

RYOJ has a net margin of 0.00% compared to Syra Health's net margin of -54.90%. RYOJ's return on equity of 0.00% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A Syra Health -54.90% -131.94% -99.19%

Do analysts prefer SYRA or DCGO?

DocGo has a consensus target price of $2.38, suggesting a potential upside of 589.40%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Syra Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation and earnings, SYRA or DCGO?

Syra Health has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syra Health $7.98M 1.52 -$2.94M $0.01 87.77 DocGo $322.20M 0.11 -$182.40M -$1.96 N/A

Is SYRA or DCGO more profitable?

Syra Health has a net margin of -54.90% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets Syra Health -54.90% -131.94% -99.19% DocGo -65.29% -40.42% -24.81%

Do analysts prefer YI or SYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, YI or SYRA?

Syra Health has lower revenue, but higher earnings than 111. 111 is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 111 $10.48B 0.00 -$9.65M -$1.60 N/A Syra Health $7.98M 1.52 -$2.94M $0.01 87.77

Is YI or SYRA more profitable?

111 has a net margin of -1.01% compared to Syra Health's net margin of -54.90%. 111's return on equity of 0.00% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets 111 -1.01% N/A -4.86% Syra Health -54.90% -131.94% -99.19%

Syra Health (SYRA) Competitors

$0.88 +0.02 (+2.08%)

As of 09/25/2026 03:37 PM Eastern

Compare

SYRA vs. BTMD, PRPO, RYOJ, DCGO, and YI

Should you buy Syra Health stock or one of its competitors? Syra Health's main competitors and comparable companies include biote (BTMD), Precipio (PRPO), RYOJ (RYOJ), DocGo (DCGO), and 111 (YI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Syra Health compare to biote?

biote (NASDAQ:BTMD) and Syra Health (NASDAQ:SYRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, biote had 2 more articles in the media than Syra Health. MarketBeat recorded 2 mentions for biote and 0 mentions for Syra Health. biote's average media sentiment score of 0.91 beat Syra Health's score of 0.00 indicating that biote is being referred to more favorably in the media.

Company	Overall Sentiment
biote	Positive
Syra Health	Neutral

21.7% of biote shares are owned by institutional investors. Comparatively, 4.8% of Syra Health shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 36.5% of Syra Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

biote has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Syra Health has a beta of 2.89, meaning that its stock price is 189% more volatile than the broader market.

biote has a net margin of 3.19% compared to Syra Health's net margin of -54.90%. biote's return on equity of -22.33% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Syra Health	-54.90%	-131.94%	-99.19%

biote has higher revenue and earnings than Syra Health. biote is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.23	$27.05M	$0.11	11.09
Syra Health	$7.98M	1.52	-$2.94M	$0.01	87.77

biote currently has a consensus price target of $2.50, indicating a potential upside of 104.92%. Given biote's stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than Syra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

biote beats Syra Health on 14 of the 17 factors compared between the two stocks.

How does Syra Health compare to Precipio?

Syra Health (NASDAQ:SYRA) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Precipio has a net margin of -4.47% compared to Syra Health's net margin of -54.90%. Precipio's return on equity of -8.49% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syra Health	-54.90%	-131.94%	-99.19%
Precipio	-4.47%	-8.49%	-5.75%

Syra Health has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market. Comparatively, Precipio has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Precipio has higher revenue and earnings than Syra Health. Precipio is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syra Health	$7.98M	1.52	-$2.94M	$0.01	87.77
Precipio	$24.05M	1.76	-$360K	-$0.64	N/A

In the previous week, Precipio had 2 more articles in the media than Syra Health. MarketBeat recorded 2 mentions for Precipio and 0 mentions for Syra Health. Precipio's average media sentiment score of 0.94 beat Syra Health's score of 0.00 indicating that Precipio is being referred to more favorably in the news media.

Company	Overall Sentiment
Syra Health	Neutral
Precipio	Positive

4.8% of Syra Health shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 36.5% of Syra Health shares are held by insiders. Comparatively, 16.6% of Precipio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Precipio beats Syra Health on 10 of the 14 factors compared between the two stocks.

How does Syra Health compare to RYOJ?

RYOJ (NASDAQ:RYOJ) and Syra Health (NASDAQ:SYRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

4.8% of Syra Health shares are held by institutional investors. 36.5% of Syra Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, RYOJ had 2 more articles in the media than Syra Health. MarketBeat recorded 2 mentions for RYOJ and 0 mentions for Syra Health. RYOJ's average media sentiment score of 0.91 beat Syra Health's score of 0.00 indicating that RYOJ is being referred to more favorably in the media.

Company	Overall Sentiment
RYOJ	Positive
Syra Health	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

RYOJ has higher revenue and earnings than Syra Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	4.72	$120K	N/A	N/A
Syra Health	$7.98M	1.52	-$2.94M	$0.01	87.77

RYOJ has a net margin of 0.00% compared to Syra Health's net margin of -54.90%. RYOJ's return on equity of 0.00% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
Syra Health	-54.90%	-131.94%	-99.19%

Summary

RYOJ beats Syra Health on 9 of the 11 factors compared between the two stocks.

How does Syra Health compare to DocGo?

Syra Health (NASDAQ:SYRA) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Syra Health has a net margin of -54.90% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syra Health	-54.90%	-131.94%	-99.19%
DocGo	-65.29%	-40.42%	-24.81%

In the previous week, DocGo had 4 more articles in the media than Syra Health. MarketBeat recorded 4 mentions for DocGo and 0 mentions for Syra Health. DocGo's average media sentiment score of 0.61 beat Syra Health's score of 0.00 indicating that DocGo is being referred to more favorably in the news media.

Company	Overall Sentiment
Syra Health	Neutral
DocGo	Positive

4.8% of Syra Health shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 36.5% of Syra Health shares are held by insiders. Comparatively, 5.1% of DocGo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DocGo has a consensus target price of $2.38, suggesting a potential upside of 589.40%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Syra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Syra Health has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market. Comparatively, DocGo has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Syra Health has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syra Health	$7.98M	1.52	-$2.94M	$0.01	87.77
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A

Summary

DocGo beats Syra Health on 10 of the 16 factors compared between the two stocks.

How does Syra Health compare to 111?

111 (NASDAQ:YI) and Syra Health (NASDAQ:SYRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

111 has a net margin of -1.01% compared to Syra Health's net margin of -54.90%. 111's return on equity of 0.00% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
111	-1.01%	N/A	-4.86%
Syra Health	-54.90%	-131.94%	-99.19%

In the previous week, 111 had 3 more articles in the media than Syra Health. MarketBeat recorded 3 mentions for 111 and 0 mentions for Syra Health. 111's average media sentiment score of 0.26 beat Syra Health's score of 0.00 indicating that 111 is being referred to more favorably in the media.

Company	Overall Sentiment
111	Neutral
Syra Health	Neutral

Syra Health has lower revenue, but higher earnings than 111. 111 is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$10.48B	0.00	-$9.65M	-$1.60	N/A
Syra Health	$7.98M	1.52	-$2.94M	$0.01	87.77

111 has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Syra Health has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market.

21.3% of 111 shares are owned by institutional investors. Comparatively, 4.8% of Syra Health shares are owned by institutional investors. 43.9% of 111 shares are owned by company insiders. Comparatively, 36.5% of Syra Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

111 beats Syra Health on 9 of the 14 factors compared between the two stocks.

Get Syra Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRA vs. The Competition

Export

Metric	Syra Health	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.16M	$9.82B	$7.34B	$13.18B
Dividend Yield	N/A	2.59%	2.52%	14.02%
P/E Ratio	-1.35	35.06	275.82	25.76
Price / Sales	1.52	5.05	610.47	82.46
Price / Cash	N/A	123.01	79.52	52.89
Price / Book	1.42	5.24	10.44	6.30
Net Income	-$2.94M	$315.70M	$3.51B	$360.35M
7 Day Performance	2.65%	0.71%	-1.31%	-0.23%
1 Month Performance	12.76%	-0.41%	-4.72%	-3.87%
1 Year Performance	N/A	16.63%	14.97%	5.38%

Syra Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRA Syra Health	N/A	$0.88 +2.1%	N/A	+779.5%	$12.16M	$7.98M	N/A	78	Gap Down
BTMD biote	4.7249 of 5 stars	$1.35 +0.7%	$2.50 +85.2%	-58.9%	$48.14M	$192.22M	12.27	223
PRPO Precipio	0.4727 of 5 stars	$26.44 -0.8%	N/A	+31.5%	$47.73M	$24.05M	N/A	71	Positive News High Trading Volume
RYOJ RYOJ	0.4871 of 5 stars	$3.66 +1.2%	N/A	N/A	$41.70M	$9.34M	N/A	N/A	News Coverage Gap Up
DCGO DocGo	2.868 of 5 stars	$0.37 -2.0%	$2.38 +536.6%	-75.2%	$37.65M	$322.20M	N/A	3,568	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRA) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syra Health (SYRA) Competitors